"The acquisition brings a team of fewer than 10 people, nearly all former Genentech computational biology researchers, into Anthropic's healthcare and life sciences division."
"Coefficient Bio had built a platform enabling AI to draft drug research and development plans, manage clinical regulatory strategies, and identify new drug candidates."
"Samuel Stanton and Nathan C. Frey, Coefficient Bio's co-founders, both came from Prescient Design, Genentech's computational drug discovery unit."
"Dimension, the New York-based venture firm, held roughly half the company and is now reporting a 38,513 per cent internal rate of return on the investment."
Anthropic has acquired Coefficient Bio, a biotech AI startup, in an all-stock deal valued at over $400 million. The acquisition includes a small team of former Genentech researchers and emphasizes the potential of general-purpose AI in drug discovery. Coefficient Bio, founded eight months ago, had no public products or revenue but was led by a team with significant credentials. The startup aimed to create artificial superintelligence for science, developing a platform for drug research and regulatory strategies.
Read at TNW | Corporates-Innovation
Unable to calculate read time
Collection
[
|
...
]